Exact Sciences

Trial results extend add to uses for Exact Sciences test

The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the test’s reach.

Exact Sciences buys cancer detection company Thrive for $2.15 billion

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and stock deal worth up to $2.15 billion, positioning it as a leader in the cancer-screening market. The Madison-based company has made …

Exact Sciences buys cancer detection company Thrive for $2.15 billion Read More »

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B

Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of 65% in Exact Sciences common stock and 35% in cash along with ~$450M as milestones related to the development and commercialization of a blood-based, multi-cancer screening test. The transaction is …

Exact Sciences to Acquire Thrive Earlier Detection for ~$2.15B Read More »

Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement

Shots: Pfizer will continue to provide sales and marketing support and health system support for Cologuard through the end of 2022 and 2021, respectively. Exact Sciences will compensate Pfizer based on the amount of services provided, along with additional fixed and performance-related fees set forth in the agreement Cologuard was approved by US FDA in …

Exact Sciences and Pfizer Announce Extension and Amendment of their Cologuard Promotion Agreement Read More »